vs

Side-by-side financial comparison of Bioventus Inc. (BVS) and Resolute Holdings Management, Inc. (RHLD). Click either name above to swap in a different company.

Bioventus Inc. is the larger business by last-quarter revenue ($157.9M vs $117.7M, roughly 1.3× Resolute Holdings Management, Inc.). Bioventus Inc. runs the higher net margin — 9.3% vs -1.5%, a 10.8% gap on every dollar of revenue. Resolute Holdings Management, Inc. produced more free cash flow last quarter ($189.2M vs $37.4M).

Bioventus Inc. is a global medical technology company specializing in orthobiologic solutions. It develops and commercializes products supporting bone and joint healing, musculoskeletal pain management, and regenerative care for patients. Its offerings serve orthopedic clinicians, physical therapists, and patients across North America, Europe, and Asia Pacific, with core segments covering surgical orthobiologics and non-surgical pain relief solutions.

Resolute Mining Limited is an Australian mining corporation focused on mining operations in Africa. It is currently operating two gold mines: the Syama Gold Mine in Mali and the Mako Gold Mine in Senegal.

BVS vs RHLD — Head-to-Head

Bigger by revenue
BVS
BVS
1.3× larger
BVS
$157.9M
$117.7M
RHLD
Higher net margin
BVS
BVS
10.8% more per $
BVS
9.3%
-1.5%
RHLD
More free cash flow
RHLD
RHLD
$151.8M more FCF
RHLD
$189.2M
$37.4M
BVS

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
BVS
BVS
RHLD
RHLD
Revenue
$157.9M
$117.7M
Net Profit
$14.8M
$-1.7M
Gross Margin
68.9%
55.7%
Operating Margin
12.3%
30.2%
Net Margin
9.3%
-1.5%
Revenue YoY
2.8%
Net Profit YoY
3902.8%
EPS (diluted)
$0.21
$-0.20

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
BVS
BVS
RHLD
RHLD
Q4 25
$157.9M
$117.7M
Q3 25
$138.7M
$120.9M
Q2 25
$147.7M
$119.6M
Q1 25
$123.9M
$103.9M
Q4 24
$153.6M
Q3 24
$139.0M
Q2 24
$151.2M
Q1 24
$129.5M
Net Profit
BVS
BVS
RHLD
RHLD
Q4 25
$14.8M
$-1.7M
Q3 25
$3.2M
$-231.0K
Q2 25
$7.5M
$-611.0K
Q1 25
$-2.6M
$-3.4M
Q4 24
$-388.0K
Q3 24
$-5.2M
Q2 24
$-25.7M
Q1 24
$-4.9M
Gross Margin
BVS
BVS
RHLD
RHLD
Q4 25
68.9%
55.7%
Q3 25
68.0%
59.0%
Q2 25
69.1%
57.5%
Q1 25
67.0%
52.5%
Q4 24
66.8%
Q3 24
67.3%
Q2 24
68.5%
Q1 24
68.3%
Operating Margin
BVS
BVS
RHLD
RHLD
Q4 25
12.3%
30.2%
Q3 25
8.1%
34.3%
Q2 25
12.4%
34.0%
Q1 25
3.9%
24.7%
Q4 24
5.0%
Q3 24
2.6%
Q2 24
-20.8%
Q1 24
3.8%
Net Margin
BVS
BVS
RHLD
RHLD
Q4 25
9.3%
-1.5%
Q3 25
2.3%
-0.2%
Q2 25
5.1%
-0.5%
Q1 25
-2.1%
-3.2%
Q4 24
-0.3%
Q3 24
-3.7%
Q2 24
-17.0%
Q1 24
-3.8%
EPS (diluted)
BVS
BVS
RHLD
RHLD
Q4 25
$0.21
$-0.20
Q3 25
$0.05
$-0.03
Q2 25
$0.11
$-0.07
Q1 25
$-0.04
$-0.39
Q4 24
$0.00
Q3 24
$-0.08
Q2 24
$-0.40
Q1 24
$-0.08

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
BVS
BVS
RHLD
RHLD
Cash + ST InvestmentsLiquidity on hand
$51.2M
$205.5M
Total DebtLower is stronger
$169.8M
Stockholders' EquityBook value
$184.1M
$6.5M
Total Assets
$683.6M
$333.4M
Debt / EquityLower = less leverage
26.03×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
BVS
BVS
RHLD
RHLD
Q4 25
$51.2M
$205.5M
Q3 25
$42.2M
$148.0M
Q2 25
$32.9M
$99.9M
Q1 25
$22.8M
$71.0M
Q4 24
$41.6M
Q3 24
$43.1M
Q2 24
$32.0M
Q1 24
$25.2M
Total Debt
BVS
BVS
RHLD
RHLD
Q4 25
$169.8M
Q3 25
$173.4M
Q2 25
$177.1M
Q1 25
$180.7M
Q4 24
Q3 24
Q2 24
Q1 24
Stockholders' Equity
BVS
BVS
RHLD
RHLD
Q4 25
$184.1M
$6.5M
Q3 25
$166.1M
$10.8M
Q2 25
$161.2M
$9.6M
Q1 25
$148.1M
$8.9M
Q4 24
$147.9M
Q3 24
$148.7M
Q2 24
$150.9M
Q1 24
$171.3M
Total Assets
BVS
BVS
RHLD
RHLD
Q4 25
$683.6M
$333.4M
Q3 25
$701.6M
$293.2M
Q2 25
$706.8M
$253.3M
Q1 25
$691.4M
$214.3M
Q4 24
$728.0M
Q3 24
$769.5M
Q2 24
$792.2M
Q1 24
$794.2M
Debt / Equity
BVS
BVS
RHLD
RHLD
Q4 25
26.03×
Q3 25
16.01×
Q2 25
18.42×
Q1 25
20.38×
Q4 24
Q3 24
Q2 24
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
BVS
BVS
RHLD
RHLD
Operating Cash FlowLast quarter
$38.0M
$196.1M
Free Cash FlowOCF − Capex
$37.4M
$189.2M
FCF MarginFCF / Revenue
23.7%
160.8%
Capex IntensityCapex / Revenue
0.4%
5.8%
Cash ConversionOCF / Net Profit
2.57×
TTM Free Cash FlowTrailing 4 quarters
$72.1M
$313.2M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
BVS
BVS
RHLD
RHLD
Q4 25
$38.0M
$196.1M
Q3 25
$30.1M
$59.6M
Q2 25
$25.9M
$48.9M
Q1 25
$-19.3M
$18.4M
Q4 24
$19.3M
Q3 24
$10.3M
Q2 24
$15.2M
Q1 24
$-6.0M
Free Cash Flow
BVS
BVS
RHLD
RHLD
Q4 25
$37.4M
$189.2M
Q3 25
$29.6M
$58.6M
Q2 25
$25.3M
$47.5M
Q1 25
$-20.2M
$17.8M
Q4 24
$18.7M
Q3 24
$10.3M
Q2 24
$15.1M
Q1 24
$-6.3M
FCF Margin
BVS
BVS
RHLD
RHLD
Q4 25
23.7%
160.8%
Q3 25
21.4%
48.5%
Q2 25
17.1%
39.7%
Q1 25
-16.3%
17.1%
Q4 24
12.2%
Q3 24
7.4%
Q2 24
10.0%
Q1 24
-4.9%
Capex Intensity
BVS
BVS
RHLD
RHLD
Q4 25
0.4%
5.8%
Q3 25
0.3%
0.8%
Q2 25
0.5%
1.2%
Q1 25
0.7%
0.6%
Q4 24
0.4%
Q3 24
0.0%
Q2 24
0.1%
Q1 24
0.2%
Cash Conversion
BVS
BVS
RHLD
RHLD
Q4 25
2.57×
Q3 25
9.54×
Q2 25
3.48×
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

BVS
BVS

Pain Treatments$71.1M45%
Surgical Solutions$48.9M31%
Restorative Therapies$19.5M12%
Other$18.4M12%

RHLD
RHLD

Segment breakdown not available.

Related Comparisons